New York State Common Retirement Fund Purchases 2,162 Shares of Surmodics, Inc. (NASDAQ:SRDX)

New York State Common Retirement Fund increased its holdings in Surmodics, Inc. (NASDAQ:SRDX) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,544 shares of the company’s stock after acquiring an additional 2,162 shares during the period. New York State Common Retirement Fund owned about 0.14% of Surmodics worth $774,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SRDX. Principal Financial Group Inc. grew its stake in Surmodics by 17.5% in the 4th quarter. Principal Financial Group Inc. now owns 36,061 shares of the company’s stock valued at $1,428,000 after purchasing an additional 5,365 shares during the period. Rhumbline Advisers boosted its holdings in shares of Surmodics by 4.4% in the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock worth $802,000 after buying an additional 861 shares during the last quarter. R Squared Ltd bought a new position in Surmodics during the fourth quarter valued at about $55,000. SG Americas Securities LLC grew its position in Surmodics by 22.1% during the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after buying an additional 1,255 shares during the period. Finally, Modus Advisors LLC purchased a new stake in Surmodics during the fourth quarter worth about $40,000. 96.63% of the stock is owned by hedge funds and other institutional investors.

Surmodics Trading Down 5.8 %

Shares of Surmodics stock opened at $30.95 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The stock has a market capitalization of $442.46 million, a P/E ratio of -30.64 and a beta of 1.20. Surmodics, Inc. has a 52-week low of $25.17 and a 52-week high of $42.44. The stock’s 50-day simple moving average is $36.31 and its 200 day simple moving average is $38.07.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. As a group, research analysts anticipate that Surmodics, Inc. will post 0.2 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on SRDX. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. StockNews.com started coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).